1. Home
  2. SEGG vs MYNZ Comparison

SEGG vs MYNZ Comparison

Compare SEGG & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lottery.com Inc.

SEGG

Lottery.com Inc.

HOLD

Current Price

$1.02

Market Cap

7.5M

Sector

Technology

ML Signal

HOLD

Logo Mainz Biomed N.V.

MYNZ

Mainz Biomed N.V.

HOLD

Current Price

$1.26

Market Cap

8.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEGG
MYNZ
Founded
N/A
2021
Country
United States
Germany
Employees
12
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
8.8M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
SEGG
MYNZ
Price
$1.02
$1.26
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$14.00
AVG Volume (30 Days)
N/A
195.9K
Earning Date
N/A
12-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$659,935.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$0.92
52 Week High
N/A
$8.20

Technical Indicators

Market Signals
Indicator
SEGG
MYNZ
Relative Strength Index (RSI) 35.39 53.19
Support Level $0.84 $1.09
Resistance Level $0.99 $1.29
Average True Range (ATR) 0.17 0.10
MACD 0.06 0.03
Stochastic Oscillator 26.40 60.56

Price Performance

Historical Comparison
SEGG
MYNZ

About SEGG Lottery.com Inc.

Lottery.com Inc is a provider of domestic and international lottery products and services. As an independent third-party lottery game service, the Company offers a platform that it developed and operates to enable the remote purchase of legally sanctioned lottery games in the U.S. and abroad. The Company's revenue-generating activities are focused on (i) offering the Platform via the Lottery.com app and its websites to users located in the U.S. and international jurisdictions where the sale of lottery games is legal and its services are enabled for the remote purchase of legally sanctioned lottery games; (ii) offering an internally developed, created and operated business-to-business application programming interface of the Platform to enable commercial partners in permitted U.S.

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Share on Social Networks: